FDA Orders GLP-1 Makers to Add NAION Warning After Study Found Roughly 2x Risk
Updated
Updated · The Washington Post · Nov 16
FDA Orders GLP-1 Makers to Add NAION Warning After Study Found Roughly 2x Risk
3 articles · Updated · The Washington Post · Nov 16
Summary
Last week’s FDA order requires GLP-1 drug makers to add labeling about a potentially higher risk of NAION, a rare “eye stroke” that can cause sudden, permanent vision loss.
The move followed more than a year of review and growing evidence, including a March study of 102,361 U.S. veterans that found semaglutide users had roughly twice the NAION risk of patients starting another diabetes drug.
Novo Nordisk and Eli Lilly said they continue to monitor safety and maintain their products have established safety profiles, while Novo cited an April analysis of more than 90,000 trial participants that found no NAION association.
The warning lands as thousands of patients sue the companies over alleged inadequate risk disclosures and as regulators in Europe, Canada, Britain and Australia have already added similar eye-risk warnings.
Beyond NAION, research on GLP-1 drugs shows mostly rare but expanding safety questions across gastrointestinal, reproductive, nutritional, bone and mental-health effects even as the medicines remain broadly effective for millions.